Proefschrift

CHAPTER 2.1 32 33. Martin SS, Ou F-S, Newby LK, Sutton V, Adams P, Felker GM, Wang TY. Patient- and Trial-Specific Barriers to Participation in Cardiovascular Randomized Clinical Trials. J Am Coll Cardiol 2013;61:762–769. 34. Vitale C, Spoletini I, Rosano G. Frailty in Heart Failure: Implications for Management. J - Frailty Heart Fail Implic Manag Radcliffe Cardiology; 2018; 35. Beckie TM, Mendonca MA, Fletcher GF, Schocken DD, Evans ME, Banks SM. Examining the Challenges of Recruiting Women Into a Cardiac Rehabilitation Clinical Trial. J Cardiopulm Rehabil Prev 2009;29:13–23. 36. Cheung AM, Lee Y, Kapral M, Scher J, Ho I, Lui-Yee D, Stewart DE. Barriers and motivations for women to participate in cardiovascular trials. J Obstet Gynaecol Can JOGC J Obstet Gynecol Can JOGC 2008;30:332–337. 37. Van Spall HGC, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 2007;297:1233–1240. 38. Lund LH, Oldgren J, James S. Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions. Curr Heart Fail Rep 2017;14:59–70. 39. Zuidgeest MGP, Goetz I, Groenwold RHH, Irving E, Thiel GJMW van, Grobbee DE. Series: Pragmatic trials and real world evidence: Paper 1. Introduction. J Clin Epidemiol 2017;88:7–13. 40. Shah RU, Chang TI, Fonarow GC. Comparative effectiveness research in heart failure therapies: women, elderly patients, and patients with kidney disease. Heart Fail Clin 2013;9:79–92. 41. Savarese G, Hage C, Benson L, Schrage B, Thorvaldsen T, Lundberg A, Fudim M, Linde C, Dahlström U, Rosano GMC, Lund LH. Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry. J Intern Med 2020; 42. McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. Eur J Heart Fail 2019;21:1402–1411. 43. World Health Organization. The world health report 2000. Health systems: improving performance. Geneva, Switzerland: World Health Organization; 2000.

RkJQdWJsaXNoZXIy MjY0ODMw